Ondansetron Injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin.
Ondansetron Injection is indicated for the prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur post operatively
DOSAGE & ADMINISTRATION:
There commended adult intravenous dosage of Ondansetron Injection is three0.15-mg/kg doses up to a maximum of 16 mg per dose. The first dose is infusedover 15 minutes beginning 30 minutes before the start of emetogenicchemotherapy. Subsequent doses are administered 4 and 8 hours after the firstdose of Ondansetron Injection.
Forpediatric patients 6 months through 18 years of age, the intravenous dosage of Ondansetron Injection is three 0.15-mg/kg doses up to a maximum of 16 mg per/dose.